News

24/7 Wall St. on MSN1d
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly and Company (LLY): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential
We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...
Eli Lilly Stock (LLY) is Stronger as it Fights for Alzheimer’s Drug Approval in Europe
Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...
Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Trade Tracker: Bill Baruch buys Eli Lilly, McDonald's, and Palantir
Bill Baruch, founder & president at Blue Line Capital, joins CNBC’s 'Halftime Report' to detail his latest portfolio moves.
Eli Lilly Files Slew of Lawsuits Over Zepbound and Mounjaro
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
Why It Makes Sense To Buy Eli Lilly Stock At $840
The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
Pharmaceutical Technology on MSN4d
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...